In a report released yesterday, Marie Thibault from BTIG maintained a Buy rating on Atricure (ATRC – Research Report), with a price target of $65.00. The company’s shares closed last Friday at $35.69.
Thibault covers the Healthcare sector, focusing on stocks such as Inari Medical, Atricure, and Insulet. According to TipRanks, Thibault has an average return of -1.8% and a 35.26% success rate on recommended stocks.
Atricure has an analyst consensus of Strong Buy, with a price target consensus of $55.57, implying a 55.70% upside from current levels. In a report released on December 21, Canaccord Genuity also maintained a Buy rating on the stock with a $50.00 price target.
See the top stocks recommended by analysts >>
ATRC market cap is currently $1.69B and has a P/E ratio of -66.46.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Atricure (ATRC) Company Description:
AtriCure, Inc. engages development, manufacture and sale of devices designed primarily for the surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio Frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, Other International, and Total International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in West Chester, OH.
Read More on ATRC:
